AEZS vs. CALC, CMMB, NRSN, NNVC, CARA, TENX, XFOR, CYTH, OVID, and IMNN
Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include CalciMedica (CALC), Chemomab Therapeutics (CMMB), NeuroSense Therapeutics (NRSN), NanoViricides (NNVC), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), X4 Pharmaceuticals (XFOR), Cyclo Therapeutics (CYTH), Ovid Therapeutics (OVID), and Imunon (IMNN). These companies are all part of the "pharmaceutical products" industry.
Aeterna Zentaris vs.
CalciMedica (NASDAQ:CALC) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.
Aeterna Zentaris has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.
CalciMedica has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
CalciMedica currently has a consensus target price of $18.00, suggesting a potential upside of 872.97%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Aeterna Zentaris.
0.7% of Aeterna Zentaris shares are owned by institutional investors. 41.5% of CalciMedica shares are owned by company insiders. Comparatively, 0.1% of Aeterna Zentaris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aeterna Zentaris received 401 more outperform votes than CalciMedica when rated by MarketBeat users. However, 94.74% of users gave CalciMedica an outperform vote while only 58.28% of users gave Aeterna Zentaris an outperform vote.
CalciMedica has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Aeterna Zentaris' return on equity of -83.45% beat CalciMedica's return on equity.
In the previous week, CalciMedica had 2 more articles in the media than Aeterna Zentaris. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Aeterna Zentaris. CalciMedica's average media sentiment score of 0.93 beat Aeterna Zentaris' score of 0.00 indicating that CalciMedica is being referred to more favorably in the media.
Summary
CalciMedica beats Aeterna Zentaris on 9 of the 17 factors compared between the two stocks.
Get Aeterna Zentaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aeterna Zentaris Competitors List
Related Companies and Tools
This page (NASDAQ:AEZS) was last updated on 6/11/2025 by MarketBeat.com Staff
